Radiation therapy.
RT is an indispensable part of current treatment approaches of locally advanced and metastatic NSCLC. It can be used alone or in combination with surgery or CHT. Because RT can potentially cure some patients, prolong the life of others, and reduce symptoms in the majority of them, it is a unique treatment modality in this disease. Radiation oncologists have learned how to deal with RT-induced toxicities and how to improve quality of life of lung cancer patients. Although recent technologic advances made sophisticated RT somewhat more expensive than before (demanding more manpower and being more time-consuming), it is still an inexpensive treatment modality, which is important in the era of focusing on cost-effectiveness. Although newer RT technologies are used to enable effective dose-escalation-a clear must for the community of radiation oncologists--optimization of RT must also include clear identification of various pretreatment, patient, and tumor-related characteristics that may influence treatment outcome. Regardless of the current therapeutic/technologic potential, we still lack some basic knowledge to better understand the process of, for example, combining RT and CHT. There is recognized need for better translational research that ultimately should be seen as a "two-way road," from laboratory to clinic and vice versa, preferably in a continuous way. The National Cancer Institute in the United States recently organized a workshop on translational research in radiation oncology, which has identified RT-CHT interactions as one of its major areas of research. Research topics include development of the methods of imaging the results of RT/ CHT interactions (confirmed by biopsy), development of new radiation modifiers, and identification of factors other than genetic ones that may influence the response of tumors to RT/CHT interactions. Tumor microenvironment was also clearly addressed as one of the targets for research, indicating as special tasks the development of new, microenvironmentally activated cytotoxic or cytostatic drugs, development and validation of more user-friendly methods for determining tumor oxygenation, and answering whether hypoxia predicts for radioresistance to CHT in treatment and whether it causes increased tumor aggression and metastasis. The future may, therefore, be quite simple: technology meets biology.
Jeremic
Branislav
B
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Strasse 22, D-81675 Munich, Germany. bjeremic@lrz.tu-muenchen.de
D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy*